Industry News
Carl Zeiss Meditec Completes Acquisition of Dutch Ophthalmic Research Center
Carl Zeiss Meditec AG has announced the successful completion of its acquisition of 100% of D.O.R.C. (Dutch Ophthalmic Research Center) from the investment firm Eurazeo SE, Paris, France, following all necessary regulatory approvals. This acquisition marks a significant milestone for ZEISS Medical Technology, expanding its ophthalmic portfolio and digitally connected workflow solutions to address a broad spectrum of eye conditions, including retina and cornea disorders, cataract, glaucoma, and refractive errors.
Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG, expressed enthusiasm about the acquisition, stating, "Together we are better. Today holds significant importance for us as we bring our teams together and turn our collective attention toward delivering breakthrough innovations and solutions for our customers."
The acquisition aims to strengthen ZEISS Medical Technology's position in the ophthalmology market, as emphasized by Euan S. Thomson, Ph.D., President of Ophthalmology and Head of the Digital Business Unit for ZEISS Medical Technology: "Together we can offer an unmatched portfolio of advanced technologies and digital workflows."
Pierre Billardon, CEO of D.O.R.C., echoed the sentiment of unity, saying, "Together we are stronger. By joining forces, we can extend our reach, scale our efforts, and accelerate ophthalmic surgery advancements for more surgeons faster than before."
The combination of Carl Zeiss Meditec AG and D.O.R.C. portfolios is expected to create an unmatched end-to-end solution within the digitally-connected ZEISS Retina Surgery Workflow. The acquisition brings D.O.R.C.'s advanced dual-function system, the EVA NEXUS platform, which complements ZEISS's visualization, diagnostic, therapeutic devices, and surgical instruments and consumables. This integration will enable the creation of efficient clinical workflows, reshaping the ophthalmology market for the benefit of surgeons and patients alike.
Health care professionals can anticipate benefiting from an extensive and unique combination of digitally connected devices and workflow solutions, supporting efficient clinical workflows and improving outcomes for patients. The immediate priorities post-acquisition include maintaining business continuity, enhancing customer satisfaction, and cultivating areas of deep expertise to provide enhanced value to customers.
The completion of the acquisition signifies a promising collaboration between Carl Zeiss Meditec AG and D.O.R.C., poised to drive significant advancements in ophthalmic surgery and patient care.
